RANK448. The biopharmaceutical company makes its debut on the Fortune 500 this year, riding the wave of a 49% year-over-year revenue increase in 2020—driven primarily by its cystic fibrosis drugs Kaftrio and Trikafta.
Similarly, Who bought Vertex?
On Oct. 18, master industrial distributor Brighton-Best International informed its customers that the company had acquired Vertex Distribution, a well-known fastener distributor, from Houston Wire & Cable Co.
Is Vertex Pharmaceuticals a buy? Good Rank and Rising Estimates: Vertex has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Vertex’s stock has declined 2.5% in the past year compared with the industry’s decline of 37%.
Thereof, What kind of company is vertex?
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
Is Vertex a good company to work for?
Is Vertex Pharmaceuticals a good company to work for? Vertex Pharmaceuticals has an overall rating of 4.1 out of 5, based on over 747 reviews left anonymously by employees. 79% of employees would recommend working at Vertex Pharmaceuticals to a friend and 82% have a positive outlook for the business.
What drugs does vertex make?
Our Approved Medicines
- KALYDECO® (ivacaftor) Medicine Name. …
- ORKAMBI® (lumacaftor/ivacaftor) …
- SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) …
- SYMKEVI® (tezacaftor/ivacaftor) + KALYDECO® (ivacaftor) …
- TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) …
- KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) + KALYDECO® (ivacaftor)
What is VRTX price target?
Vertex Pharmaceuticals Inc (NASDAQ:VRTX)
The 21 analysts offering 12-month price forecasts for Vertex Pharmaceuticals Inc have a median target of 278.00, with a high estimate of 350.00 and a low estimate of 222.00.
Is VRTX a buy Zacks?
Vertex Pharmaceuticals Incorporated – Buy
Zacks’ proprietary data indicates that Vertex Pharmaceuticals Incorporated is currently rated as a Zacks Rank 2 and we are expecting an above average return from the VRTX shares relative to the market in the next few months.
What sector is Vertex Pharmaceuticals in?
Vertex Pharmaceuticals serves healthcare sector worldwide.
What makes Vertex Pharmaceuticals unique?
We have a unique way of building our drug discovery programs to maximize their chances of creating therapies that may dramatically improve patients’ lives. We focus on serious diseases where we can have a transformative impact for patients, not just an incremental benefit.
What is vertex working now?
Vertex Pharmaceuticals is developing a stem cell-derived therapy for the treatment of type 1 diabetes (T1D) called VX-880. On Oct. 18, the company gave an update on the first patient dosed with VX-880 in a phase 1/2 clinical trial for the treatment.
What products does Vertex Pharmaceuticals make?
Our Approved Medicines
- KALYDECO® (ivacaftor) Medicine Name. …
- ORKAMBI® (lumacaftor/ivacaftor) …
- SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) …
- SYMKEVI® (tezacaftor/ivacaftor) + KALYDECO® (ivacaftor) …
- TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) …
- KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) + KALYDECO® (ivacaftor)
Is AstraZeneca a good place to work?
85% of employees at AstraZeneca say it is a great place to work compared to 57% of employees at a typical U.S.-based company. Source: Great Place to Work® 2021 Global Employee Engagement Study.
Is vertex a good company to work for?
Is Vertex Pharmaceuticals a good company to work for? Vertex Pharmaceuticals has an overall rating of 4.1 out of 5, based on over 747 reviews left anonymously by employees. 79% of employees would recommend working at Vertex Pharmaceuticals to a friend and 82% have a positive outlook for the business.
How effective is Kalydeco?
In the U.S. cohort, patients taking Kalydeco had a decrease in FEV of 0.7%, whereas the reduction for those not taking the treatment was 8.3%. In the U.K. cohort, the therapy improved pulmonary function (increase of 4.9% in FEV values), compared to FEV decrease of 4.3% in patients not receiving Kalydeco.
Where is Kaftrio manufactured?
Authorisation details
| Publication details | |
|---|---|
| Marketing-authorisation holder | Vertex Pharmaceuticals (Ireland) Limited |
| Revision | 7 |
| Date of issue of marketing authorisation valid throughout the European Union | 21/08/2020 |
| Contact address | Unit 49, Block F2, Northwood Court, Santry Dublin 9, D09 T665 Ireland |
Will VRTX go up?
Given the current short-term trend, the stock is expected to rise 16.47% during the next 3 months and, with a 90% probability hold a price between $291.49 and $328.16 at the end of this 3-month period.
How high is FedEx stock?
FedEx Corp (NYSE:FDX)
The 26 analysts offering 12-month price forecasts for FedEx Corp have a median target of 292.50, with a high estimate of 333.00 and a low estimate of 230.00. The median estimate represents a +43.15% increase from the last price of 204.33.
Is ABBV a buy Zacks?
Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). Even though a company’s earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues.
What medications does vertex make?
Our Approved Medicines
- KALYDECO® (ivacaftor) Medicine Name. …
- ORKAMBI® (lumacaftor/ivacaftor) …
- SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) …
- SYMKEVI® (tezacaftor/ivacaftor) + KALYDECO® (ivacaftor) …
- TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) …
- KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) + KALYDECO® (ivacaftor)
Join TheMoney.co community and don’t forget to share this post !
